<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294227</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457F2336</org_study_id>
    <secondary_id>2014-003849-10</secondary_id>
    <nct_id>NCT02294227</nct_id>
  </id_info>
  <brief_title>16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis</brief_title>
  <acronym>FUTURE 4</acronym>
  <official_title>A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to provide 16-week efficacy, safety and tolerability data
      versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.)
      self-administration with or without a loading regimen and maintenance dosing using pre-filled
      syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with
      active PsA despite current or previous NSAID or DMARD therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2015</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">February 16, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With American College of Rheumatology 20 (ACR20) Response</measure>
    <time_frame>16 weeks</time_frame>
    <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria:
Health Assessment Questionnaire - Disability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS-C28-CRP) Score Change From Baseline Using MMRM at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>DAS28-CRP score change from baseline using MMRM up to Week 16. DAS-CRP values range between 2.0 and 10. The higher the score, the higher the disease severity.
n: Number of subjects with measures at both baseline and the corresponding post baseline visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriatic Area and Severity Index 75 (PASI75)</measure>
    <time_frame>16 weeks</time_frame>
    <description>PASI is a measure of disease activity based on extent of the disease, severity of erythema, scaling and thickness in different body areas affected by psoriasis. PASI75 is an improvement in the PASI score of at least 75% compared to baseline. PASI75 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
PASI75 response using non-responder imputation and rescue penalty up to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Health Survey Physical Component Score (SF-36-PCS)</measure>
    <time_frame>16 weeks</time_frame>
    <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With American College of Rheumatology 50 (ACR50)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The ACR50 response is defined by at least 50% decrease in the swollen and tender joint count, and at least 50% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)].
ACR50 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
This table is the ACR50 response using non-responder imputation and rescue penalty up to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With American College of Rheumatology 20 (ACR20) Response</measure>
    <time_frame>4 weeks</time_frame>
    <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire - Diability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">341</enrollment>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>Secukinumab 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab 150 mg No load</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.</description>
    <arm_group_label>Secukinumab 150 mg</arm_group_label>
    <arm_group_label>Secukinumab 150 mg No load</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Psoriatic Arthritis (PsA) classified by ClASsification criteria for
             Psoriatic ARthritis (CASPAR) criteria.

          -  Rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies negative.

          -  Diagnosis of active plaque psoriasis or nail changes consistent with psoriasis.

          -  Inadequate control of symptoms with NSAID.

          -  Other protocol-defined inclusion criteria do apply.

        Exclusion Criteria:

          -  Chest X-ray or chest magnetic resonance imaging (MRI) with evidence of ongoing
             infectious or malignant process.

          -  Subjects taking high potency opioid analgesics.

          -  Previous exposure to secukinumab or other biologic drug directly targeting
             interleukin-17 (IL-17) or IL-17 receptor.

          -  Ongoing use of prohibited psoriasis treatments / medications.

          -  Subjects who have ever received biologic immunomodulating agents except for those
             targeting TNFÎ±.

          -  Previous treatment with any cell-depleting therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Clair Shores</city>
        <state>Michigan</state>
        <zip>48081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruntal</city>
        <state>Czech Republic</state>
        <zip>792 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hlucin</city>
        <state>Czech Republic</state>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <state>Czech Republic</state>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 4</city>
        <state>Czech Republic</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <state>Czech Republic</state>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dopiewo</city>
        <zip>62 069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poznan</city>
        <zip>61 113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leytonstone</city>
        <state>London</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>http://www.novartisclinicaltrials.com</url>
    <description>Introduction to clinical trials conducted by Novartis and to results of completed studies, with the aim of increasing the transparency of Novartis clinical research and making publicly available objective scientific information in a standardised format.</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <results_first_submitted>November 8, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2019</results_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIN457</keyword>
  <keyword>psoriatic arthritis</keyword>
  <keyword>chronic inflammatory disease</keyword>
  <keyword>loading regimen</keyword>
  <keyword>secukinumab</keyword>
  <keyword>self-injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 341 patients originally randomized to one of 2 trearment groups. Seven placebo patients discontinued before week 16 and therefore not switched to treatment. Only 334 patients received secukinumab treatment.</recruitment_details>
      <pre_assignment_details>Patients were randomized 1:1:1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab 150 mg</title>
          <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="P2">
          <title>Secukinumab 150 mg No Load</title>
          <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab 150 mg</title>
          <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="B2">
          <title>Secukinumab 150 mg No Load</title>
          <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="114"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="107"/>
            <count group_id="B4" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="12.17"/>
                    <measurement group_id="B2" value="50.4" spread="11.78"/>
                    <measurement group_id="B3" value="48.5" spread="12.12"/>
                    <measurement group_id="B4" value="49.0" spread="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response</title>
        <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria:
Health Assessment Questionnaire - Disability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.</description>
        <time_frame>16 weeks</time_frame>
        <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response</title>
          <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria:
Health Assessment Questionnaire - Disability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.</description>
          <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.66</ci_lower_limit>
            <ci_upper_limit>5.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Chi-squared, Corrected</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.76</ci_lower_limit>
            <ci_upper_limit>5.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (DAS-C28-CRP) Score Change From Baseline Using MMRM at Week 16</title>
        <description>DAS28-CRP score change from baseline using MMRM up to Week 16. DAS-CRP values range between 2.0 and 10. The higher the score, the higher the disease severity.
n: Number of subjects with measures at both baseline and the corresponding post baseline visit.</description>
        <time_frame>week 16</time_frame>
        <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS-C28-CRP) Score Change From Baseline Using MMRM at Week 16</title>
          <description>DAS28-CRP score change from baseline using MMRM up to Week 16. DAS-CRP values range between 2.0 and 10. The higher the score, the higher the disease severity.
n: Number of subjects with measures at both baseline and the corresponding post baseline visit.</description>
          <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
          <units>scores</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.106"/>
                    <measurement group_id="O2" value="-0.84" spread="0.106"/>
                    <measurement group_id="O3" value="-0.21" spread="0.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriatic Area and Severity Index 75 (PASI75)</title>
        <description>PASI is a measure of disease activity based on extent of the disease, severity of erythema, scaling and thickness in different body areas affected by psoriasis. PASI75 is an improvement in the PASI score of at least 75% compared to baseline. PASI75 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
PASI75 response using non-responder imputation and rescue penalty up to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <population>The psoriasis subset included all full analysis set (FAS) patients who had â¥3% of the body surface area (BSA) affected by psoriatic skin involvement at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriatic Area and Severity Index 75 (PASI75)</title>
          <description>PASI is a measure of disease activity based on extent of the disease, severity of erythema, scaling and thickness in different body areas affected by psoriasis. PASI75 is an improvement in the PASI score of at least 75% compared to baseline. PASI75 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
PASI75 response using non-responder imputation and rescue penalty up to Week 16</description>
          <population>The psoriasis subset included all full analysis set (FAS) patients who had â¥3% of the body surface area (BSA) affected by psoriatic skin involvement at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="4.90" upper_limit="42.38"/>
                    <measurement group_id="O2" value="27" lower_limit="4.14" upper_limit="35.19"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Health Survey Physical Component Score (SF-36-PCS)</title>
        <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
        <time_frame>16 weeks</time_frame>
        <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo Non-responder</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Health Survey Physical Component Score (SF-36-PCS)</title>
          <description>SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline of at least one dose of secukinumab versus placebo. The SF-36 is a validated instrument measuring health-related quality of life across multiple disease states. It has 36 questions with 8 subscale scores and 2 summary scores (1) physical component summary=physical functioning, role-physical, bodily pain, and general health. There is no total overall score; scoring is done for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score. Change from Baseline= post-Baseline - Baseline value.</description>
          <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.5676"/>
                    <measurement group_id="O2" value="3.44" spread="0.5678"/>
                    <measurement group_id="O3" value="0.63" spread="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With American College of Rheumatology 50 (ACR50)</title>
        <description>The ACR50 response is defined by at least 50% decrease in the swollen and tender joint count, and at least 50% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)].
ACR50 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
This table is the ACR50 response using non-responder imputation and rescue penalty up to Week 16</description>
        <time_frame>16 weeks</time_frame>
        <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With American College of Rheumatology 50 (ACR50)</title>
          <description>The ACR50 response is defined by at least 50% decrease in the swollen and tender joint count, and at least 50% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)].
ACR50 is used to assess the efficacy of secukinumab, with or without loading, versus placebo.
This table is the ACR50 response using non-responder imputation and rescue penalty up to Week 16</description>
          <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response</title>
        <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire - Diability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo</description>
        <time_frame>4 weeks</time_frame>
        <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 150 mg</title>
            <description>Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg No Load</title>
            <description>Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With American College of Rheumatology 20 (ACR20) Response</title>
          <description>The ACR20 response is defined by at least 20% decrease in the swollen and tender joint count, and at least 20% improvement in 3 of the following 5 criteria: Health Assessment Questionnaire - Diability Index, pain score on a visual analog scale, patient global assessment of disease activity, physician global assessment of disease activity and acute phase reactant [either erythrocyte sedimentation rate (ESR) or high sensitivity C-reactive protein (hsCRP)]. ACR20 is used to assess the efficacy of secukinumab, with or without loading, versus placebo</description>
          <population>Full Analysis Set (FAS): all subjects from the randomized set to whom study treatment has been assigned.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately week 112</time_frame>
      <desc>Safety analysis is based on actual dose received. Pts who escalated from 150mg to 300mg are also analyzed at escalated dose Any AIN457 150 mg (n = 334): 114 AIN150 Load + 113 AIN150 No Load + 107 PBO-AIN150 Any AIN457 (n = 334): 114 AIN150 Load + 113 AIN150 No Load + 107 PBO-AIN150 Any AIN457 300mg (n=136): 46 up-titrators from AIN150 load + 45 up-titrators from AIN150 No Load + 45 up-titrators from PBO - AIN300 Placebo (n=114): 114 patients were randomized to the placebo arm</desc>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 150 mg</title>
          <description>Any AIN457 150 mg</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 300 mg</title>
          <description>Any AIN457 300 mg</description>
        </group>
        <group group_id="E3">
          <title>Any AIN457</title>
          <description>Any AIN457</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Undifferentiated sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cervicogenic headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Device fastener issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ureteric compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="252" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="267" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="334"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="334"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Disclosure Office</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

